Suchergebnisse - "Koole, Simone N"

PubPharm (16)

1

Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications

enthalten in: The Lancet. Oncology | 2024

von Koole, S. | Huisman, A. | Timmers, L. | +4

2

Differences in time to patient access to innovative cancer medicines in six European countries

enthalten in: International journal of cancer | 2024

von Vancoppenolle, J. | Franzen, N. | Koole, S. | +2

3

Differences in time to patient access to innovative cancer medicines in six European countries

enthalten in: International Journal of Cancer | 2024

von Vancoppenolle, J. | Franzen, N. | Koole, S. | +2

4

Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1) : final survival analysis of a randomised, controlled, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Aronson, S. | Lopez-Yurda, M. | Koole, S. | +15

CommentIn: Lancet Oncol. 2023 Oct;24(10):1057-1059. - PMID 37797627

5

Targeted combination therapies in oncology : Challenging regulatory frameworks designed for monotherapies in Europe

enthalten in: Drug discovery today | 2023

von Vancoppenolle, J. | Koole, S. | O'Mahony, J. | +4

6

Reply to : Comments on "Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial"

enthalten in: International journal of cancer | 2022

von Koole, S. | Schouten, P. | van Driel, W. | +2

CommentOn: Int J Cancer. 2022 Oct 15;151(8):1394-1404. - PMID 35583992

7

Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer : Results from the phase III OVHIPEC trial

enthalten in: International journal of cancer | 2022

von Koole, S. | Schouten, P. | Hauke, J. | +24

CommentIn: Int J Cancer. 2022 Dec 01;151(11):2057-2058. - PMID 35857410

8

Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer : Costs, Time to Diagnosis and Clinical Relevance

enthalten in: Cancers | 2022

von Koole, S. | Vessies, D. | Schuurbiers, M. | +9

9

Reply to : Comments on “Effect of HIPEC according to HRD/ BRCA wt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial”

enthalten in: International Journal of Cancer | 2022

von Koole, S. | Schouten, P. | Driel, W. | +2

10

Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer

enthalten in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society | 2020

von Koole, S. | Bruijs, L. | Fabris, C. | +13